Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux101 enrolled

Overview

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Elvitegravir/Cobicistat/FTC/Tenofovir alafenamide (E/C/F/TAF) for four Weeks. Elvitegravir is an HIV-1 integrase strand transfer inhibitor (INSTI). Cobicistat is a selective, mechanism-based inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A subfamily. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue àf 2'-dexicytidine. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonoamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

101

Conditions

HIV Risk

Interventions

GenvoyaDRUG

Oral use (one tablet each day); 150/150/200/10 mg; 28 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * an age above 18 years * consultation within 48 hours following a risk of HIV transmission (blood or sexual contact) * indication for HIV post-exposure prophylaxis (according to French guidelines) * person able to understand the nature of the study * person who signed his consent form to participate in the study Exclusion Criteria: * person exposed to HIV risk from person infected by HIV, whose therapeutic history justifies the prescription of another combination of antiretroviral drugs * contraindications to the prescription of Genvoy * other medical contraindications * person infected by hepatitis B virus * pregnant or lactating woman

Locations (16)

Hôpital Jean Minjoz

Besançon, France

Hôpital Saint-André

Bordeaux, France

CHU Ambroise Paré

Boulogne-Billancourt, France

Outcomes

Primary Outcomes

Proportion of patients taking the uninterrupted HIV post-exposure prophylaxis for four weeks

Time frame: Day 28

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.